Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HRID 227686Generated: October 25, 2026

1-Fluoronaphthalene → N,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amine

https://huagongshe.com/reaction/227686

Reaction equation

Participants

RoleNameHCIDCharge
Reactant1-FluoronaphthaleneHCID 9450—
ReactantDuloxetineHCID 60835—
Reactant2,3:4,6-di-O-Isopropylidene-2-keto-L-gulonic acidHCID 65420—
Reactant(S)-mandelic acidHCID 439616—
Reactant3-(Dimethylamino)-1-(2-thienyl)-1-propanolHCID 11586409—
ProductN,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amineHCID 11573192—

Reaction Steps

The preparation of the enantiomerically pure duloxetine intermediate (S)-AT-OL by its chiral resolution is exemplified in U.S. Pat. No. 5,362,886 (U.S. '886) and in WO 2004/031168, by the use of (S)-(+)-mandelic acid and (−)-2,3:4,6-Di-O-isopropylidene-2-keto-L-gulonic acid, respectively. The U.S. '886 patent describes the preparation of duloxetine by the chiral resolution of N,N-Dimethyl-3-(2-thienyl)-3-hydroxypropanamine (rac-AT-OL) with (S)-mandelic acid (Stage a), its reaction with fluoronaphtalene (Stage b) to give N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine (DNT), demethylation with phenyl chloroformate (Stage c), basic hydrolysis in the presence of (Stage d), and acidification (Stage e) in accordance with the following Scheme 1.

Provenance & Evidence

DOI10.6084/m9.figshare.5104873.v1
Patent numberUS07560573B2
Source datasetuspto-grants-2009_07
ORD IDord-b4e13c2f94f946e48272c9a7635dea3d
Source noteuspto-grants-2009_07